Delivery Order SPE2DB22D3011-SPE2DB25FQ2BM
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) at a ceiling value of $6,286.98. This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor. The performance location is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL pharmaceutical product. This is a firm fixed price delivery order with a ceiling value of $2,583.60 and an ultimate completion date of July 28, 2025. The contract was awarded without a set-aside designation through competitive procurement, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $9.68K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on July 23, 2025, with completion expected by July 24, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M vehicle extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5ml units) with a ceiling value of $3,644.71 under a firm fixed-price contract. This delivery order represents a non-set-aside competitive award and is child to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $49,798.78 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml pharmaceutical products. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 21, 2025. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,348.64 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in respiratory treatment. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $2,583.60 delivery order to AmerisourceBergen Drug Corp for PULMOZYME 1 mg/ml ampules (2.5 ml units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with the Defense...
- The Defense Logistics Agency (DLA) awarded a $48,488.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units). The contract, which was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This delivery order is issued under...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The firm-fixed-price contract has a ceiling value of $2,583.60 and a period of performance through April 28, 2025. The contract is not set aside for any specific business type. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2BMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,342.71 on July 31, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml pharmaceutical product. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania, scheduled for completion by August 1, 2025. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The SPE2DX IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of pharmaceuticals, specialty medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency and other government healthcare system requirements worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.3k | 7/31/25 |